Tag

Chiesi Global Rare Diseases

8 minuti di lettura

Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) in the EU

Committee for Medicinal Products for Human Use (CHMP) issues a positive opinion following re-examination, which will be reviewed by the European Commission (EC), with a decision anticipated by March 2026 If

Video pillole

Malattie rare, Lampe: “Grande onore far parte di comitato di selezione di Find for Rare”

(Adnkronos) – “È stata un’emozione ed è stato un grande onore far parte della comunità di Find for Rare e valutare la diverse proposte di ricerca ricevute, una più interessante dell’altra. Penso che abbiamo scelto i migliori anche se, in

Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) in the EU

Immediapress

Committee for Medicinal Products for Human Use (CHMP) issues a positive opinion following re-examination, which will be reviewed by the European Commission (EC), with

Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) in the EU

Immediapress

Committee for Medicinal Products for Human Use (CHMP) issues a positive opinion following re-examination, which will be reviewed by the European Commission (EC), with

Chiesi Global Rare Diseases

Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) in the EU

Malattie rare, Lampe: “Grande onore far parte di comitato di selezione di Find for Rare”

Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) in the EU

Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) in the EU

Primo piano

Conte incontra gli autotrasportatori e sfida Meloni: “Misure tampone, prendere risorse da chi ha accumulato” | Video

Sabato blindato a Roma: quattro piazze in un giorno, ecco chi sfila e dove

Torino: ipotesi 8 condotta a chi ha occupato il Liceo Gioberti, tensione tra le famiglie

Proteste ed effetto contagio: quando il caos nelle piazze arriva allo spread e alle nostre tasche

Sponsor

Suggerimenti

Chiesi Global Rare Diseases

Primo piano

Sponsor